As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought more than 25 biopharmaceutical products to market. Boehringer Ingelheim Biopharma Contract Manufacturing is represented by its brand Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry. The services comprise the entire production technology chain from DNA to fill and finish under one brand at its facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle-transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.
Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. There the company will establish a new large-scale biopharmaceutical production facility for active ingredients manufactured using cell cultures. With the roughly half billion euro investment Boehringer Ingelheim will also create more than 400 new jobs in the Austrian capital. The new production plant will go into operation by 2021.
More information: www.bioxcellence.com
About VTU Technology
VTU Technology, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VTU develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins.
Headquartered in Grambach/Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in chemistry, pharma & life science. The VTU group currently counts more than 420 highly qualified people working in several subsidiaries in different European countries. From 2013 to 2015, the VTU group was able to boost its turnover from 40 million euros to 72 million euros. More information: www.vtu-technology.com, www.vtu.com
Contact Boehringer Ingelheim:
Mag. Inge Homolka
Communications Austria
Boehringer Ingelheim RCV GmbH & Co KG
Dr. Boehringer-Gasse 5 – 11
A-1121 Wien
Tel. +43-1-80105-2230
Email: ingeborg.homolka@boehringer-ingelheim.com
Contact VTU Technology:
Dr. Thomas Purkarthofer
Head of Business Development
Parkring 18
A-8074 Raaba-Grambach
Tel: +43-316-4009-4017
Email: thomas.purkarthofer@vtu.com